JP7606966B2 - ミトコンドリア病を標的とするアナログ - Google Patents

ミトコンドリア病を標的とするアナログ Download PDF

Info

Publication number
JP7606966B2
JP7606966B2 JP2021533856A JP2021533856A JP7606966B2 JP 7606966 B2 JP7606966 B2 JP 7606966B2 JP 2021533856 A JP2021533856 A JP 2021533856A JP 2021533856 A JP2021533856 A JP 2021533856A JP 7606966 B2 JP7606966 B2 JP 7606966B2
Authority
JP
Japan
Prior art keywords
ischemia
acid
compound
compounds
pharma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021533856A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022514241A5 (cg-RX-API-DMAC7.html
JP2022514241A (ja
Inventor
ヂォン,グオヂュー
ジェイ バンバーガー,マーク
スムクステ,イネセ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stealth Biotherapeutics Inc
Original Assignee
Stealth Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Biotherapeutics Inc filed Critical Stealth Biotherapeutics Inc
Publication of JP2022514241A publication Critical patent/JP2022514241A/ja
Publication of JP2022514241A5 publication Critical patent/JP2022514241A5/ja
Application granted granted Critical
Publication of JP7606966B2 publication Critical patent/JP7606966B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021533856A 2018-12-18 2019-11-19 ミトコンドリア病を標的とするアナログ Active JP7606966B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862781156P 2018-12-18 2018-12-18
US62/781,156 2018-12-18
PCT/US2019/062284 WO2020131283A1 (en) 2018-12-18 2019-11-19 Analogs that target mitochondrial diseases

Publications (3)

Publication Number Publication Date
JP2022514241A JP2022514241A (ja) 2022-02-10
JP2022514241A5 JP2022514241A5 (cg-RX-API-DMAC7.html) 2022-11-21
JP7606966B2 true JP7606966B2 (ja) 2024-12-26

Family

ID=71101584

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021533856A Active JP7606966B2 (ja) 2018-12-18 2019-11-19 ミトコンドリア病を標的とするアナログ

Country Status (9)

Country Link
US (2) US12252554B2 (cg-RX-API-DMAC7.html)
EP (1) EP3898653A4 (cg-RX-API-DMAC7.html)
JP (1) JP7606966B2 (cg-RX-API-DMAC7.html)
KR (1) KR102995415B1 (cg-RX-API-DMAC7.html)
CN (1) CN113383005A (cg-RX-API-DMAC7.html)
AU (1) AU2019401254B2 (cg-RX-API-DMAC7.html)
CA (1) CA3123610A1 (cg-RX-API-DMAC7.html)
IL (1) IL284014A (cg-RX-API-DMAC7.html)
WO (1) WO2020131283A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113544138B (zh) 2018-12-18 2024-10-29 隐形生物治疗公司 线粒体靶向肽
WO2020131283A1 (en) 2018-12-18 2020-06-25 Stealth Biotherapeutics Corp. Analogs that target mitochondrial diseases
US20240197623A1 (en) * 2021-04-07 2024-06-20 Stealth Bio Therapeutics Inc. Silica-based formulations of therapeutic oliogpeptides and peptidomimetics
KR102876070B1 (ko) * 2023-02-08 2025-10-24 웰펩 주식회사 신규 펩티도미메틱을 유효성분으로 포함하는 아토피 피부염의 예방 또는 치료용 조성물
WO2026151834A1 (en) 2025-01-09 2026-07-16 Stealth Biotherapeutics Inc. Compounds for use in medical management of subjects with muscular dystrophy
WO2026151846A1 (en) 2025-01-09 2026-07-16 Stealth Biotherapeutics Inc. Compositions for use in the treatment of heart failure, idiopathic cardiomyopathy, dilated cardiomyopathy, restrictive cardiomyopathy, hypertrophic cardiomyopathy, or hypertensive cardiomyopathy

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013531682A (ja) 2010-07-09 2013-08-08 ステルス ペプチドズ インターナショナル インコーポレイテッド 虚血/再灌流障害に続くノーリフローの予防又は処置方法
JP2016511259A (ja) 2013-03-01 2016-04-14 ステルス バイオセラピューティックス コープ バース症候群の予防または治療のための方法及び組成物
WO2016144352A2 (en) 2015-03-11 2016-09-15 Stealth Peptides International, Inc. Therapeutic compositions including acrylamido compounds or phenyl-substituted maleimide compounds, variants thereof and methods of using the same
WO2017093897A1 (en) 2015-11-30 2017-06-08 Peter Schiller Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
WO2017117381A1 (en) 2015-12-31 2017-07-06 Scott Duncan Therapeutic compositions including peptides and uses thereof
WO2017201433A1 (en) 2016-05-19 2017-11-23 Stealth Biotherapeutics Corp Compositions and methods for the prevention and treatment of mitochondrial myopathies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2656854T1 (sl) 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
CA2787331A1 (en) * 2010-01-25 2011-07-28 Hazel H. Szeto Aromatic-cationic peptides and uses of same
EP2808029A3 (en) 2010-03-15 2015-04-01 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
US8383919B2 (en) 2010-12-14 2013-02-26 Xueyun Gao Highly fluorescent peptide-metallic nanoclusters as bio-probes and methods of synthesis thereof
EP3108975A1 (en) 2011-03-24 2016-12-28 Cornell University Aromatic-cationic peptides and uses of same
CA2865409C (en) 2012-02-23 2020-07-21 Cornell University Aromatic-cationic peptides and uses of same
CA2916492A1 (en) 2013-06-27 2014-12-31 Stealth Biotherapeutics Corp Peptide therapeutics and methods for using same
CN106459169A (zh) 2014-03-03 2017-02-22 康德生物医疗技术公司 药学上相关的芳香族阳离子肽
WO2015183984A2 (en) 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including tocopherol and uses thereof
US10870678B2 (en) 2016-04-11 2020-12-22 Arcuate Therapeutics, Inc. Chiral peptides
WO2018186404A1 (ja) * 2017-04-03 2018-10-11 出光興産株式会社 有機エレクトロルミネッセンス素子及び電子機器
WO2018223032A1 (en) 2017-06-02 2018-12-06 Stealth Biotherapeutics Corp. Crystalline salt forms of sbt-20
US20200361987A1 (en) 2017-11-15 2020-11-19 Stealth Biotherapeutics Corp. Deuterated tetrapeptides that target mitochondria
CN113544138B (zh) 2018-12-18 2024-10-29 隐形生物治疗公司 线粒体靶向肽
WO2020131283A1 (en) 2018-12-18 2020-06-25 Stealth Biotherapeutics Corp. Analogs that target mitochondrial diseases

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013531682A (ja) 2010-07-09 2013-08-08 ステルス ペプチドズ インターナショナル インコーポレイテッド 虚血/再灌流障害に続くノーリフローの予防又は処置方法
JP2016511259A (ja) 2013-03-01 2016-04-14 ステルス バイオセラピューティックス コープ バース症候群の予防または治療のための方法及び組成物
WO2016144352A2 (en) 2015-03-11 2016-09-15 Stealth Peptides International, Inc. Therapeutic compositions including acrylamido compounds or phenyl-substituted maleimide compounds, variants thereof and methods of using the same
WO2017093897A1 (en) 2015-11-30 2017-06-08 Peter Schiller Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
WO2017117381A1 (en) 2015-12-31 2017-07-06 Scott Duncan Therapeutic compositions including peptides and uses thereof
WO2017201433A1 (en) 2016-05-19 2017-11-23 Stealth Biotherapeutics Corp Compositions and methods for the prevention and treatment of mitochondrial myopathies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The FASEB Journal,2015年,Vol.29,pp.4589-4599

Also Published As

Publication number Publication date
CN113383005A (zh) 2021-09-10
AU2019401254A1 (en) 2021-06-24
WO2020131283A1 (en) 2020-06-25
EP3898653A1 (en) 2021-10-27
KR20210093958A (ko) 2021-07-28
US20220041654A1 (en) 2022-02-10
AU2019401254B2 (en) 2025-05-01
KR102995415B1 (ko) 2026-07-23
CA3123610A1 (en) 2020-06-25
US20260008810A1 (en) 2026-01-08
US12252554B2 (en) 2025-03-18
EP3898653A4 (en) 2022-08-24
JP2022514241A (ja) 2022-02-10
IL284014A (en) 2021-08-31

Similar Documents

Publication Publication Date Title
US20260008810A1 (en) Analogs that target mitochondrial diseases
JP7576670B2 (ja) ミトコンドリア標的化ペプチド
US20260055136A1 (en) Mitochondria-targeting peptides
JP2023017813A (ja) 内在化ペプチド連結薬剤と抗炎症剤との共投与
US20240092832A1 (en) Deuterated tetrapeptides that target mitochondria
JP2003514920A (ja) 抗血管新生活性を有するn−アルキル化ペプチド
EP4168423A1 (en) Prodrugs of mitochodria-targeting oligopeptides
US20230227499A1 (en) Prodrugs of mitochondria-targeting oligopeptides
US20240059734A1 (en) Mitochondria-targeting peptides
JP6222779B2 (ja) 心血管治療法
HK40039982B (en) Mitochondria-targeting peptides

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230921

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241011

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241018

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241216

R150 Certificate of patent or registration of utility model

Ref document number: 7606966

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150